CareDx, a leader in precision medicine for transplant care, and Dovetail Genomics, a pioneer in genomic solutions, have announced a strategic partnership to revolutionize HLA genotyping for organ and stem cell transplants. The collaboration integrates CareDx’s AlloSeq Tx 17, the first NGS-based HLA typing solution covering 17 loci, with Dovetail Genomics’ Hi-C LinkPrep technology.
This approach enables high-resolution haplotyping without requiring family genotyping, enhancing the precision of donor-recipient matching and potentially improving transplant outcomes. CareDx’s AlloSeq Tx 17 employs a hybrid-capture workflow that streamlines donor-matching studies and expands gene content for in-depth results, while Dovetail’s LinkPrep technology introduces direct phasing information to produce comprehensive HLA haplotypes.
CareDx, headquartered in Brisbane, California, is dedicated to developing clinically differentiated healthcare solutions for pre-and post-transplant patient care. Through its testing services and digital solutions, the company is a leader in genomics-based information for transplant patients. Meanwhile, Dovetail Genomics specializes in proximity ligation technologies, advancing understanding of genome architecture and haplotype phasing. This collaboration underscores both companies’ commitment to innovation in genomics and transplant care.
